AzTrials
AzTrials

Healthy VolunteerSWEETNCT06997133

Sucralose as a Way to Enhance Regulatory T Cells

A study testing sucralose in people with Healthy Volunteer, run by Caroline Lamarche at 1 site in Canada.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Title: Taking the SWEET approach to protect the transplanted kidney. Background: Kidneys are essential organs in our body. When they do not work, patients require machines to help them or receive a new kidney from a donor (transplantation) to survive. Thus far, transplantation is the best treatment. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Healthy Volunteer
What is being tested?
sucralose
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
10 participants
Where
1 siteCanada
Study dates
1 Sep 2025to 1 Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Body weight comparable to average reported in Canada

Who cannot join

  • Past medical history of autoimmune disease
  • The use of any regular medication except contraceptive pills
  • Pregnant women

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Julianna Blagih, PhD contact

514-252-3400

juliannablagih@gmail.com

Canada1 site
  • Centre de recherche de l'Hôpital Maisonneuve-Rosemont

    Montreal, Quebec, H1T2M4

    Caroline Lamarche, MD, MSc, 514-252-3400 ext. 8682, caroline.lamarche.1@umontreal.ca

    Caroline Lamarche, MD, MSc

Other trials in Canada

About this study

Official title: Sucralose as a Way to Enhance Regulatory T Cells: The Sweet Trial

Title: Taking the SWEET approach to protect the transplanted kidney.

Background: Kidneys are essential organs in our body. When they do not work, patients require machines to help them or receive a new kidney from a donor (transplantation) to survive. Thus far, transplantation is the best treatment. However, the immune system will recognize the new kidney as foreign and try to destroy it, which is called kidney rejection. To prevent rejection, patients with kidney transplants depend on drugs to suppress the immune system. However, these drugs have many side effects, including the risk of infection, cancer, and diabetes.

Read more

The immune system is made of many different types of cells. One cell type in particular is T cells that, when kept unchecked, will attack the kidney transplant. However, there is a small subset of these T cells called regulatory T cells (Tregs) that police the immune system and aid in accepting the new kidney. Current ways to increase these police cells (Tregs) after a transplant are expensive and not widely available. Therefore, there is a need to find a better and more accessible way to increase Treg numbers after a transplant to increase the longevity of the newly transplanted kidney.

What we eat is critical in shaping the immune system. Artificial sweeteners, like sucralose (found in Splenda), are often used as a sugar substitute. They are low in calories and safe to consume. However, recent studies suggest they may have unexpected effects on the body. Research in mice has shown that sucralose impacts the immune system. Specifically, the investigators have found that it could suppress T cells that could cause kidney rejection while increasing the Tregs (the police).

Given these findings, the investigators hypothesize that sucralose could be beneficial in conditions where dampening the immune system is desirable, such as in the case of transplantation. By boosting Tregs and reducing the anti-transplant T cells, sucralose may help to protect against organ rejection.

Purpose: The goal of this study is thus to test whether sucralose can safely and effectively modulate the immune system in humans.

Method: The investigator propose to test the impact of sucralose on the immune system. This pilot study will test the effect of sucralose in 10 healthy volunteers. The participants will take sucralose or placebo as a pill twice daily for a month. Healthy volunteers will then stop for a two weeks (washout period). After the washout period, the volunteers on sucralose will switch to placebo, while the placebo group will switch to sucralose pills for one more months. The investigators will take blood samples at the beginning, after one month, after the washout and at the end of the study to study how the immune system changes.

Anticipated outcomes: The investigators expect that sucralose will impact the immune system and increase the number of regulatory T cells.

Relevance to patient/community: Artificial sweeteners are commonly used in the food and pharmaceutical industries. However, their impact on the immune system has not been thoroughly investigated in humans.

Conclusion: Kidney transplantation is the most effective treatment for kidney failure, but the immune system's rejection of the transplanted organ remains a major challenge. Current immunosuppressive drugs used to prevent rejection have significant side effects, underscoring the need for safer alternatives. The investigator research suggests that sucralose, a widely used artificial sweetener, may offer a novel solution by increasing the good T cells (Tregs) and reducing harmful T cells that contribute to rejection. This pilot study will explore sucralose's potential to modulate the immune system in humans, potentially leading to improved transplant outcomes and broader implications for immune regulation.

Being tested
sucralose, Placebo
Keywords
sucralose, immune system, regulatory T cells, metabolomic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • sucraloseDietary supplement

    Encapsulated sucralose po BID

  • PlaceboOther

    Encapsulated lactose po bid

Study groups in NCT06997133
Study groupRoleWhat they receive
Starting with placebo - washout - sucralose.Placebo comparatorThis group will start with a placebo (4 weeks) , then will have a washout period (2 weeks) and then will test sucralose (4 weeks)
Receives: Dietary Supplement: sucralose; Other: Placebo
Starting with sucralose - washout - placebo.Active comparatorThis group will start with sucralose (4 weeks) , then will have a washout period (2 weeks) and then will test the placebo (4 weeks)
Receives: Dietary Supplement: sucralose; Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Regulatory T cells

    Change in % regulatory T cells on total CD4+ T cells compared to baseline

    Measured: After 4 weeks on sucralose and placebo.

Secondary outcomes (4)
  1. T cell cytokine production (TNFa, IFNy, IL2)

    % cytokine production o CD4+ and CD8+ T cells

    Measured: 4 weeks compared to baseline on either placebo or sucralose

  2. Frequency of immune populations in the blood (CD4+, CD8+, NK, B cells, CD11b myeloid cells)

    % of CD45+ cells (total immune marker)

    Measured: 4 weeks compared to baseline on either sucralose or placebo

  3. Frequency of CD4+ T cells lineages

    % RORyt, T-bet, GATA3 on CD4+ T cells

    Measured: 4 weeks compared to baseline on sucralose or placebo

  4. Frequency of naive, central and effector memory or terminally differentiated CD4+ and CD8+ T cells

    % of CD62L+CD45RA+CD45RO- (naive), CD62L+CD45RO+CD44+CD45RA- (central memory), CD62L-CD45RA-CD45RO+CD44+ (effector memory) and CD62L-CD45RA+CD45RO (terminally differentiated cells) on both CD4+ and CD8+ T cells

    Measured: 4 weeks compared to baseline on both sucralose or placebo

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 May 2025
  2. Study start1 Sep 2025 (estimated)
  3. Primary completion1 Sep 2026 (estimated)
  4. Study completion1 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06997133
Sponsor's protocol ID
2025-3912
Acronym
SWEET
Status last verified
Jan 2025
First submitted
20 Dec 2024
Last updated
5 Jun 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Bourguignon L, Benazzouk Y, Bokou-Gianneli E, Zani F, Blagih J, Lamarche C. Sucralose as a Way to Enhance Regulatory T Cells, the SWEET Trial: Clinical Research Protocol. Can J Kidney Health Dis. 2026 Feb 13;13:20543581261418540. doi: 10.1177/20543581261418540. eCollection 2026.

    PubMed 41694241

Questions about this trial

What is this clinical trial studying?

A study testing sucralose in people with Healthy Volunteer, run by Caroline Lamarche at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 5 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Caroline Lamarche, MD, MSc (514-252-3400 ext. 8682, caroline.lamarche.1@umontreal.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Regulatory T cells (time frame: After 4 weeks on sucralose and placebo.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06997133, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in